v3.25.1
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities    
Net income (loss) $ (56,569) $ 102,875
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 1,046 1,507
Stock-based compensation expense 5,372 7,319
Impairment of out-license asset and remeasurement of CVR liability, net   6,772
Gain on Sale Transactions, net   (153,647)
Inventory write-downs, net   2,481
Change in fair value of derivatives 12,608 194
Other non-cash adjustments, net 858 (2,889)
Changes in operating assets and liabilities:    
Trade receivables, net 50,891 8,579
Inventory (22,244) (11,455)
Prepaid manufacturing 188 9,589
Other prepaid, current and non-current assets (5,334) (4,426)
Accounts payable 13,042 616
Accrued rebates, fees and reserves (17,129) (15,157)
TSA related operating assets and liabilities, net (Note 6) (1,836) (1,424)
Accrued compensation 1,606 1,559
Accrued and other current and non-current liabilities (8,325) 741
Net cash used in operating activities (25,826) (46,766)
Investing activities    
Proceeds from maturities of investments in marketable securities   6,200
Proceeds from sale of investments in marketable securities   8,688
Milestone payment to Junshi Biosciences (12,500)  
Other investing activities, net (267) 52
Net cash provided by (used in) investing activities (17,486) 202,763
Financing activities    
Taxes paid related to net share settlement (264) (745)
Other financing activities   125
Net cash (used in) provided by financing activities (264) 887
Net increase (decrease) in cash, cash equivalents and restricted cash (43,576) 156,884
Cash, cash equivalents and restricted cash at beginning of period 126,250 103,343
Cash, cash equivalents and restricted cash at end of period 82,674 260,227
CIMERLI ophthalmology franchise    
Investing activities    
Cash received from(paid) related to the Sale Transactions (Note 6) $ (4,719) 187,823
ATM Offering    
Financing activities    
Proceeds from issuance of common stock, net of issuance costs   $ 1,507